Glenmark Pharma rises on USFDA nod for prostate cancer drug

20 May 2022 , 12:18 PM

The approved ANDA is the generic versions of the Zytiga Tablet manufactured by Janssen Biotech Inc. Abiraterone acetate tablets are used in combination to treat certain type of prostate cancer. According to IQVIA sales data for the year ended March 2022, the Zytiga Tablets market achieved annual sales of approximately $260.2 million. Glenmarks current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 49 ANDAs pending approval with the United States Food and Drug Administration (USFDA). Glenmark Pharmaceuticals is an innovation-driven global pharmaceutical company with a presence across specialty, generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 manufacturing facilities spread across 4 continents and operations in over 80 countries. The drug makers consolidated net profit fell 3.4% to Rs 239.75 crore on a 13.9% rise in net sales to Rs 3,141.47 crore in Q3 FY22 over Q3 FY21. Powered by Capital Market – Live News